HC Wainwright Analysts Cut Earnings Estimates for Indaptus Therapeutics, Inc. (NASDAQ:INDP)

Indaptus Therapeutics, Inc. (NASDAQ:INDP) – Research analysts at HC Wainwright reduced their Q1 2024 earnings estimates for Indaptus Therapeutics in a research note issued to investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.57) per share for the quarter, down from their previous forecast of ($0.44). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q2 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.34) EPS and FY2024 earnings at ($1.83) EPS.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07.

Indaptus Therapeutics Trading Down 4.7 %

Shares of INDP opened at $2.66 on Wednesday. Indaptus Therapeutics has a 12 month low of $1.56 and a 12 month high of $4.08. The firm has a fifty day simple moving average of $2.13 and a 200 day simple moving average of $2.10. The stock has a market capitalization of $22.72 million, a price-to-earnings ratio of -1.45 and a beta of 1.28.

Institutional Trading of Indaptus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC bought a new stake in Indaptus Therapeutics during the fourth quarter worth $29,000. Northern Trust Corp bought a new stake in Indaptus Therapeutics during the first quarter worth $41,000. Renaissance Technologies LLC bought a new stake in Indaptus Therapeutics during the second quarter worth $51,000. State Street Corp bought a new stake in Indaptus Therapeutics during the first quarter worth $78,000. Finally, Vanguard Group Inc. raised its position in Indaptus Therapeutics by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after acquiring an additional 5,517 shares in the last quarter. 7.06% of the stock is owned by institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.